High materiality7/10
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
Why it may matterVerify against the original reporting
Upside potential remains despite near-term pullback.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
BMO Capital raises PTGX target to $190 from $178; current price $147.75; slight pullback since signal.
- BMO raises PTGX target to $190; price $147.75.
Key facts
- 01
Target: $190
- 02
Posted price: $147.75
- 03
Analyst firm: BMO Capital
- 04
Analyst: Evan Seigerman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.